Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to regrow hair in alopecia patients

NCT ID NCT07049328

Recruiting now Disease control Sponsor: HCW Biologics Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tests a new drug called HCW9302 in 30 adults with alopecia areata, a condition causing patchy or total hair loss. The drug is an IL-2 fusion protein given by injection. The main goal is to check safety and find the right dose for future studies, not to prove it works yet.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HCW9302, an IL-2 fusion protein
What this could lead to
If this works, it could point toward a new treatment that helps regrow hair in people with alopecia areata.
What could go wrong
This is a very early, small Phase 1 trial focused on safety, not effectiveness. The drug may not work or could cause side effects. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALOPECIA AREATA(AA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alopecia alopecia areata

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALOPECIA AREATA(AA)

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • James A. Haley Veterans' Hospital

    RECRUITING

    Tampa, Florida, 33612, United States

  • The Ohio State University Wexner Medical Center

    RECRUITING

    Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.